Kenvue Sees Unusually High Options Volume (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) saw some unusual options trading on Tuesday. Traders acquired 106,657 call options on the company. This is an increase of approximately 851% compared to the typical daily volume of 11,211 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KVUE shares. UBS Group boosted their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Jefferies Financial Group assumed coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $22.64.

Institutional Trading of Kenvue

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Kenvue by 12.0% in the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after purchasing an additional 17,908,497 shares during the last quarter. FMR LLC increased its stake in Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kenvue by 23.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock worth $2,887,773,000 after acquiring an additional 25,238,112 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Kenvue by 11.1% during the 1st quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock valued at $1,466,147,000 after acquiring an additional 6,825,611 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock traded up $0.32 during trading hours on Thursday, hitting $23.46. The company’s stock had a trading volume of 1,378,587 shares, compared to its average volume of 18,005,434. The company has a market cap of $44.98 billion, a PE ratio of 42.05, a PEG ratio of 2.15 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50 day moving average price of $22.72 and a two-hundred day moving average price of $20.62. Kenvue has a 12-month low of $17.67 and a 12-month high of $23.95.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the previous year, the firm earned $0.31 EPS. The firm’s revenue was down .4% compared to the same quarter last year. Analysts expect that Kenvue will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.50%. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.